Phase 3 Uveitis Trial, Not Yet Recruiting NCT07136805 Sponsor: VivaVision Biotech, Inc Condition: Uveitis
Back to Uveitis

Phase 3 Uveitis Trial, Not Yet Recruiting

NCT07136805
Not Yet Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 70 years old (inclusive) at the time of signing the consent form
  • At your screening visit, one of your eyes has been diagnosed with non-infectious anterior uveitis (either an acute episode or a recurring acute episode, affecting one eye only)
  • At your screening visit, the level of inflammation (measured by cells in the front part of the eye) in the affected eye is at a moderate to moderately severe level, rated 2+ or 3+ using a standard medical scale (confirm with trial site)
  • At your screening visit, there is also a measurable amount of flare (a cloudiness caused by inflammation) in the affected eye, rated 1 or higher on the same standard scale (confirm with trial site)

Who may not be able to join:

  • At your screening visit, the inflammation in the affected eye is at the most severe level (rated 4+), or there is a visible buildup of inflammatory cells at the bottom of the eye (called hypopyon)
  • You have been diagnosed with a type of uveitis that affects the middle, back, or the whole eye (rather than just the front), in either eye, at the time of screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8618816562189

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
VivaVision Biotech, Inc
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
31 December 2026

Primary endpoints

Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov